NASDAQ:ELOS Syneron Medical (ELOS) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free ELOS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$11.00▼$11.0050-Day Range N/A52-Week Range$6.18▼$11.43VolumeN/AAverage Volume562,777 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Syneron Medical alerts: Email Address Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Syneron Medical Stock (NASDAQ:ELOS)Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company's aesthetic medical products are based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company's products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, tattoo removal, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, and laser-assisted lipolysis.Read More Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… ELOS Stock News HeadlinesMarch 13, 2024 | uk.investing.comApax Global Alpha Ltd (APAX)November 14, 2023 | morningstar.comElos Medtech AB Class B ELOS BMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!August 21, 2023 | thestreet.comSyneron Medical Stock Hits New 52-Week Low (ELOS)July 13, 2023 | wsj.comElos Medtech AB Series BJune 15, 2023 | thestreet.comSyneron Hires Finance ChiefMay 11, 2023 | marketwatch.comRadio Frequency Beauty Instrument Market 2023 Size, Share and Trends Analysis – Syneron Medical, Lumenis, Valeant Pharmaceutical InternationalJanuary 21, 2023 | cnbc.comAs of July 1, your medical debt may no longer hurt your credit score—here's whyMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!January 18, 2022 | thestreet.comSyneron Medical Stock Hits New 52-Week High (ELOS)January 7, 2022 | thestreet.comSyneron Medical (ELOS) Stock Spikes Today on Strong Fourth Quarter GuidanceSee More Headlines Receive ELOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syneron Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/04/2016Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:ELOS CUSIPN/A CIK1291361 Websyneron-candela.com Phone+972-7-32442200FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesShimon Eckhouse Ph.D.Chairman of the BoardAmit MeridorChief Executive OfficerBio & Compensation - Hugo GoldmanChief Financial OfficerBio & Compensation - Erik DowellVice President-North AmericaWilliam GriffingChief Executive Officer - Syneron Candela North AmericaShlomo AlkalayChief Operating OfficerLisa A. SoderquistChief Human Resource OfficerBio & Compensation - Robert RuckExecutive Vice President, Asia PacificRobert FielitzVice President and Managing Director of Europe, Middle East and AfricaSarit Soccary Ben-YochananVice President - Business Development & StrategyMore Executives ELOS Stock Analysis - Frequently Asked Questions How were Syneron Medical's earnings last quarter? Syneron Medical Ltd (NASDAQ:ELOS) announced its quarterly earnings data on Thursday, August, 4th. The medical equipment provider reported $0.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. The medical equipment provider had revenue of $75 million for the quarter, compared to the consensus estimate of $75.72 million. The firm's quarterly revenue was up 2.0% compared to the same quarter last year. During the same period last year, the business posted $0.07 earnings per share. What other stocks do shareholders of Syneron Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syneron Medical investors own include Micron Technology (MU), Advanced Micro Devices (AMD), BIOLASE (BIOL), Cisco Systems (CSCO), Freeport-McMoRan (FCX), Gilead Sciences (GILD), Lannett (LCI), Rite Aid (RAD), Ambarella (AMBA) and Citigroup (C). This page (NASDAQ:ELOS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syneron Medical Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.